"On behalf of the board and all our employees, I want to thank Alvin for his tremendous contributions to the rapid progression of our pipeline," said
"While I am sad to leave Retrophin, I'm incredibly proud of the progress we have made towards delivering new therapies for rare disease patients," said
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products Thiola®, Cholbam® and Chenodal®.
Chris Cline, CFA Senior Director, Investor Relations 646-564-3680 IR@retrophin.com
News Provided by Acquire Media